DOCMORRIS AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 91 CHF | +3.47% |
|
-2.05% | +23.39% |
| 10:41am | DOCMORRIS : Warburg Research reiterates its Buy rating | ZD |
| 09:05am | DOCMORRIS : UBS reaffirms its Sell rating | ZD |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Zur Rose Group AG is a Switzerland-based company engaged in the drug distribution sector. The Company focuses on the wholesale trade of medicines, as well as operation of a mail-order pharmacy. The Company's activities are divided into two business segments: Zur Rose and DocMorris. The Zur Rose division includes wholesale business and provides drugs to medical doctors, health insurance companies, hospitals and healthcare companies, among others. The DocMorris division manages the mail-order business for drug retail. The Company operates in Switzerland, Germany and the Netherlands through a number of subsidiaries, such as Zur Rose Suisse AG, Zur Rose Pharma GmbH, BlueCare AG, DocMorris NV, Eurapon Pharmahandel GmbH and Vitalsana BV.
Sector
Drug Retailers
Calendar
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
87.95
CHF
Average target price
95.49
CHF
Spread / Average Target
+8.57%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +23.39% | 1.13B | |
| -32.06% | 15.23B | |
| -40.54% | 9.9B | |
| -4.53% | 6.83B | |
| +9.14% | 6.1B | |
| -38.21% | 5.59B | |
| +5.40% | 5B | |
| +49.08% | 4.21B | |
| -11.42% | 3.65B | |
| -11.73% | 3.46B |
- Stock Market
- Equities
- ROSE Stock
- News DocMorris AG
- Zur Rose : Revenue Grows 18% in First Nine Months of 2021; FY21 Revenue Growth Guidance Downgraded
